Traditional Chinese Herbs Target Cellular Senescence to Fight Blood Cancers

Cellular senescence — a state of permanent cell cycle arrest — has emerged as a critical mechanism in both cancer suppression and cancer progression. In hematological malignancies such as leukemia, lymphoma, and myeloma, senescence pathways are often dysregulated, allowing malignant cells to evade growth controls while exploiting the inflammatory senescence-associated secretory phenotype (SASP) to thrive.

This review from researchers at the Affiliated Hospital of Nanjing University of Chinese Medicine synthesizes recent advances in understanding how cellular senescence contributes to the pathogenesis of blood cancers. The authors focus specifically on how inducing senescence in tumor cells — rather than suppressing it — has become an emerging therapeutic strategy.

Traditional Chinese herbal medicine (TCM) is presented as a promising modality for inducing senescence in hematological tumor cells. The review outlines three primary molecular mechanisms: telomere shortening (which triggers replicative senescence), induction of DNA damage responses (activating checkpoint pathways), and regulation of SASP factors (modulating the inflammatory tumor microenvironment). These mechanisms collectively push malignant cells into a non-proliferative senescent state.

The appeal of TCM in this context lies in its reported combination of therapeutic efficacy with a relatively favorable toxicity profile compared to conventional chemotherapeutics. The authors suggest that TCM compounds could serve as standalone or complementary agents in treating hematological malignancies, potentially reducing treatment-associated side effects.

Importantly, this is a narrative review with no new clinical or preclinical data generated. The evidence base relies on existing studies, which vary in quality and translatability. The mechanisms described are largely derived from in vitro and animal models, and robust clinical trial evidence for TCM-induced senescence in blood cancers remains limited.